Lacosamide Solution
Product Images NDC 85742-014

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 85742-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kanchan Healthcare Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Containerlabel200ml (Containerlabel200ml)

Containerlabel200ml (Containerlabel200ml)
This text contains information about a medication labeled as "Lacosamide Oral Solution, USP" in a 200mL container. Each mL of the solution contains 10 mg of Lacosamide. The recommended storage temperature range is between 15°C to 30°C. The text also instructs pharmacists to dispense the medication to patients and keep it out of the reach of children. The manufacturer is identified as Kanchan Healthcare Inc. Additionally, the text mentions the usual dosage, storage conditions, and manufacturing details.*
FDA Label Image

Containerlabel465ml (Containerlabel465ml)

Containerlabel465ml (Containerlabel465ml)
This is a product description for Lacosamide Oral Solution, USP. It contains important information for pharmacists, such as dosage details, storage instructions, expiration date, and warnings related to phenylketonurics. The solution comes in a 465mL bottle and each mL contains 10 mg of Lacosamide. It is important to dispense the medication guide to each patient. The manufacturer is Medley Pharmaceuticals Ltd., and the product is distributed by Kanchan Healthcare Inc. It's recommended to keep the product out of reach of children and store it between 20°C to 25°C (68°F to 77°F).*
FDA Label Image

Figure 3 (Figure3)

Figure 3 (Figure3)
FDA Label Image

Table (Figure4)

Table (Figure4)
This document provides a detailed guideline on the dosage titration regimen and maintenance dosage for the use of a medication in different age groups and body weight categories. It includes specific dosing instructions for adults, pediatric patients weighing at least 50 kg, pediatric patients weighing between 30 kg to less than 50 kg, pediatric patients weighing between 11 kg to less than 30 kg, and pediatric patients weighing less than 6 kg. The document also clarifies the dosage adjustments for monotherapy and adjunctive therapy for partial-onset seizures and primary generalized tonic-clonic seizures. Additionally, it highlights that the medication is indicated only for partial-onset seizures.*
FDA Label Image

Lacosamide Fig 01 (Lacosamide Fig1)

Lacosamide Fig 01 (Lacosamide Fig1)
FDA Label Image

Lacosamide Fig 02 (Lacosamide Fig2)

Lacosamide Fig 02 (Lacosamide Fig2)
FDA Label Image

Lacosamide Fig 03 (Lacosamide Fig3)

Lacosamide Fig 03 (Lacosamide Fig3)
This text describes the Responder Rate of Lacosamide compared to Placebo in Studies 2, 3, and 4. It shows the percentage of patients categorized as responders and non-responders to different doses of Lacosamide. The figure displays the proportions for placebo, Lacosamide 200mg/day, Lacosamide 400mg/day, and Lacosamide 600mg/day. It provides valuable information on the improvement and worsening effects observed in these studies.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.